Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

Benjamin M. Stermole, Greg A. Grandits, Mollie P. Roediger, Brychan M. Clark, Anuradha Ganesan, Amy C. Weintrob, Nancy F. Crum-Cianflone, Tomas M. Ferguson, Grace E. Macalino, Michael L. Landrum

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


We analyzed HIV viral load (VL) and CD4 count changes, and antibody responses following MMR vaccination of individuals in the U.S. Military HIV Natural History Study cohort. Cases receiving at least one dose of MMR vaccine after HIV diagnosis were matched 1:2 to HIV-positive controls not receiving the vaccine. Baseline was defined as time of vaccination for cases and indexed and matched to the time post-HIV diagnosis for controls. Changes in CD4 count and VL at 6, 12, 18 and 24 months were compared between cases and controls using a general linear model. Available sera from cases were tested for MMR seropositivity at baseline and post-vaccination at 6, 12, 18, and 24 months. Overall mean CD4 count change from baseline through 24 months was 20 (±23) cells/μL greater for cases than controls (p=0.39). Similar non-significant changes in CD4 cell count were seen in the subset of those not on HAART at baseline. VL changes were small and similar between groups (mean differential change -0.04 (±0.18) log10 copies/mL; p=0.84). Of 21 vaccinated participants with baseline serologic testing, 14 (67%) were reactive to measles, 19 (91%) to mumps, and 20 (95%) to rubella. Three (43%) of 7 participants nonreactive to measles developed measles IgG; for mumps, 1 (50%) of 2 developed mumps IgG; for rubella, 1 (100%) developed rubella IgG. MMR vaccination did not result in detrimental immunologic or virologic changes through 24 months post-vaccination.

Original languageEnglish (US)
Pages (from-to)2874-2880
Number of pages7
Issue number16
StatePublished - Apr 5 2011

Bibliographical note

Funding Information:
Support for this work (IDCRP-000-10) was provided by the Infectious Disease Clinical Research Program (IDCRP) , a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072.


  • Human immunodeficiency virus
  • MMR Vaccine
  • Measles
  • Mumps
  • Vaccination
  • Vaccines

Fingerprint Dive into the research topics of 'Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults'. Together they form a unique fingerprint.

Cite this